Safety pharmacology continues to dominate the agenda in preclinical and clinical drug development. A well designed and executed safety pharmacology strategy will characterise pro-arrhythmic risk of products in development.

Following on from a exceptional launch event in 2007 Safety Pharmacology World Europe is here again. This year’s event brings together top pharmaceutical, biotechnology and regulatory representatives in a forum that will provide you with a comprehensive review:

Attending this event will be your most valuable 2 days spent out of the office in 2008. It will transform the way you approach future of cardiac safety, allowing you to consolidate your competitive gains and capitalise on future opportunities.